Top five most-read articles from ACR State-of-the-Art Clinical Symposium
Click Here to Manage Email Alerts
CHICAGO — The most highly read articles on www.Healio.com/Rheumatology following live coverage from the American College of Rheumatology State-of-the-Art Clinical Symposium included research on rheumatoid arthritis, statin myalgia, and the need for careful thinking and planning when making clinical decisions.
‘Creativity’ needed for treatment of difficult RA symptoms, speaker says
Daniel Furst , MD, a Carl Pearson Professor of Medicine and director of the Rheumatology Clinical Research Center at the University of California Los Angeles School of Medicine, said rheumatologists need to “get creative” in the treatment of rheumatoid arthritis (RA) and use the best-known data to combine therapies for patients with symptoms that are difficult to resolve. Read more.
Andrew L. Mammen , MD, PhD, speaks about statin myalgia
Statins can cause myalgia, and symptoms can take months or years to resolve, according to Andrew L. Mammen, MD, PhD, who presented research during a session, here. Read more.
Careful medication choices can help reduce infection risk posed by certain treatments for RA
Treatments for rheumatoid arthritis can pose risks for infections, but careful choices about medications can reduce the risks, according to a presentation by Daniel Furst, MD. Read more.
Speaker: Radiography remains first line of clinical imaging assessment
Despite advances in imaging technologies, radiography remains a useful, first-choice tool in assessing rheumatic disease, such as RA and gout, as well as disease activity and progression, according to Imran Omar, MD, who spoke at the symposium. Read more.
Certain common viral illnesses may present in patients with inflammatory rheumatic disease
Beth L. Jonas, MD, discussed the common viral illnesses that may present alongside inflammatory rheumatic diseases, including hepatitis A, hepatitis B, hepatitis C, parvovirus B19 and chikungunya, and some symptoms can mimic rheumatic disease. Read more.